Finoriq research workspace
BridgeBio Oncology Therapeutics, Inc. (BBOT) Company Overview
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development. Review BBOT filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
- Company
- BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Ticker
- BBOT
- Market Cap
- $673.7M
- Latest Price
- $8.41
- Industry
- Biotech & Pharma
BridgeBio Oncology Therapeutics, Inc. (BBOT) Current Valuation Metrics
Static valuation preview for BridgeBio Oncology Therapeutics, Inc. (BBOT). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -18.5% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -15.7% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 1.76x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.